Document Detail


In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
MedLine Citation:
PMID:  19401346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This study was undertaken to evaluate the effects of MDX-1401, a nonfucosylated fully human monoclonal antibody that binds to human CD30, and to determine whether it exhibits greater in vitro and in vivo activity than its parental antibody. EXPERIMENTAL DESIGN: Assays measuring antibody binding to CD30-expressing cells and FcgammaRIIIa (CD16) transfectants as well as antibody-dependent cellular cytotoxicity (ADCC) were conducted. Antitumor activity was determined using a Karpas-299 systemic model. RESULTS: The binding of MDX-1401 to CD30 antigen was identical to fucose-containing parental anti-CD30 antibody (MDX-060). In contrast, MDX-1401 showed increased binding affinity to FcgammaRIIIa-transfected cells resulting in increased effector function. MDX-1401 greatly improved ADCC activity as evidenced by a decrease in half-maximal effective concentration (EC(50)) and an increase in maximum cell lysis when compared with MDX-060. Increased ADCC activity was observed among a panel of cell lines, including one with very low CD30 antigen expression in which parental antibody failed to induce any detectable ADCC. MDX-1401 activity with all FcgammaRIIIa polymorphic variants, including less active Phe/Phe158 and Phe/Val158 effector cells, was shown. Furthermore, MDX-1401 was efficacious in inhibiting tumor growth in CD30(+) lymphoma xenografts. CONCLUSIONS: The low doses of antibody required for ADCC activity irrespective of donor genotype, the ability to mediate ADCC in target cells expressing low levels of CD30, and increased in vivo efficacy support the development of MDX-1401 for treatment of malignant lymphoma.
Authors:
Pina M Cardarelli; Maria-Cristina Moldovan-Loomis; Ben Preston; Amelia Black; David Passmore; Tseng-Hui Chen; Sharline Chen; Jie Liu; Michelle R Kuhne; Mohan Srinivasan; Albert Assad; Alison Witte; Robert F Graziano; David J King
Related Documents :
8354486 - Immunohistochemical characteristics of hodgkin and reed-sternberg cells in relation to ...
2297046 - Cutaneous t-cell lymphoma cells employ a restricted range of t-cell antigen receptor va...
790006 - Immunological characterization of lymphoproliferative disorders by membrane markers.
8701936 - Angiocentric immunoproliferative lesions of the lymph node.
8094396 - Use of monoclonal antibodies specific for the a determinant of k88 pili for detection o...
377666 - Antibodies to donor b lymphocytes and autoantibodies in renal transplantation.
Publication Detail:
Type:  Journal Article     Date:  2009-04-28
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  15     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-19     Completed Date:  2009-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3376-83     Citation Subset:  IM    
Affiliation:
Department of Cell Biology and Pharmacology, Medarex, Sunnyvale, CA 94089, USA. pcardarelli@medarex.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / chemistry,  immunology,  pharmacology*
Antibody Affinity / drug effects,  immunology
Antibody-Dependent Cell Cytotoxicity / drug effects
Antigens, CD30 / immunology
Binding Sites, Antibody / immunology
CHO Cells
Carbohydrates / chemistry,  immunology
Cell Line, Tumor
Cricetinae
Cricetulus
Dose-Response Relationship, Drug
Fucose / chemistry,  immunology
Humans
Lymphoma / drug therapy*,  immunology,  pathology
Male
Mice
Mice, SCID
Receptors, IgG / chemistry,  immunology
Xenograft Model Antitumor Assays*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD30; 0/Binding Sites, Antibody; 0/Carbohydrates; 0/FCGR3A protein, human; 0/MDX-1401; 0/Receptors, IgG; 3713-31-3/Fucose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells.
Next Document:  {gamma}H2AX Expression in Tumors Exposed to Cisplatin and Fractionated Irradiation.